MCL
Haematology · 2016–2025
8decisions
4medicines
8carried consumer input
23individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| acalabrutinib Previously untreated Stage III or IV mantle cell lymphoma in patients ineligible for autologous stem cell transplantation, in combination with bendamustine and… | Jul 2025 | Recommended | input received |
| acalabrutinib Treatment of patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy and have a WHO performance status of 0 or 1. | Jul 2021 | Recommended with restriction | input received Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| zanubrutinib Treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy and have a WHO performance status of… | Jul 2021 | Recommended with restriction | input received Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia |
| ibrutinib Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) that is relapsed or refractory to at least one prior therapy, and mantle cell lymphoma… | Nov 2020 | Recommended | input received Leukaemia Foundation |
| ibrutinib Two conditions: (1) relapsed or refractory mantle cell lymphoma; (2) first-line treatment of patients with chronic lymphocytic leukaemia or small lymphocytic… | Mar 2018 | Recommended with restriction | 2 individuals |
| ibrutinib Treatment of relapsed or refractory mantle cell lymphoma in patients who have received at least one prior therapy. | Nov 2017 | Recommended with restriction | input received |
| lenalidomide Treatment of relapsed and/or refractory mantle cell lymphoma in adult patients following at least one prior first-line therapy who are unable to tolerate… | Jul 2016 | Not recommended | input received |
| ibrutinib Treatment of relapsed or refractory mantle cell lymphoma in patients who have received at least one prior therapy. | Nov 2016 | Not recommended | 21 individuals |
Who spoke
Leukaemia Foundation · Lymphoma Australia · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.